Anatoly Dritschilo, MD.

PETALUMA, Calif.—RetinalGeniX Technologies Inc. (OTCQB: RTGN), an ophthalmic research and development med-device and therapeutic drug development company focused on creating high-resolution retinal imaging and pharmaco-genetic mapping technologies, has announced that Anatoly Dritschilo, MD has joined the company’s medical advisory board. Dr. Dritschilo is the CEO and chairman of the board of directors of Shuttle Pharmaceuticals Holdings, Inc. Formerly, as an educator and translational scientist, he was employed at Georgetown University and the MedStar Georgetown University Hospital as a radiation oncologist and chairman of the department of radiation medicine.

Over a 40-plus year career, he has provided clinical services to thousands of patients presenting with cancers of the breast, prostate and the central nervous system.

"I look forward to working with the Retinalgenix team of clinicians and scientists to address the need for biomarker technology for guiding diagnosis and management of systemic diseases that may be reflected in the eye,” said Dr. Dritschilo.

In concert with its pharmaco-genetic mapping software, the company is developing a high-resolution 24/7 real-time home and remote monitoring system to assist both physicians and patients. The use of the system does not require dilation of the pupil. The combined technologies are intended to prevent blindness through the early detection and treatment of ocular diseases and systemic diseases including neurodegenerative, cardiovascular, vascular, metabolic and diabetic conditions.

The company is making progress in conducting pharmaceutical clinical studies for treating dry age-related macular degeneration (AMD) through Avania, its contract research organization (CRO). Additionally, the company is developing plans to conduct a future study of alzheimer's/dementia complex as part of the DNA/RNA GPS initiative.

RetinalGeniX has also filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study that is intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.

Jerry Katzman MD, chairman, president and CEO of RetinalGeniX Technologies Inc., said, “We are thrilled to welcome Dr. Dritschilo as a senior consultant to assist with our pharmaco-genetic anti-VEGF study and the suitability of ocular injection therapy to patients prior to its use. Dr. Anatoly will oversee many aspects of the study with Dr. Larry Perich and Fred Chasalow, PhD, on different aspects of their work. Dr. Dritschilo's accomplishments are truly remarkable. We are looking forward to working together to advance our anti-VEGF study for the benefit of patients worldwide.”